Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders — Stella

Recruiting

Back to Neuromyelitis Optica Spectrum Disorder trials

Trial locations(1 site)

China

Xuanwu Hospital, Capital Medical University, Beijing, Beijing Municipality

Key details

Sponsor

Xuanwu Hospital, Beijing

Enrollment target

~50 participants

Started

July 2024

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated September 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov